• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe

IPOs

Now Available: IPO Guidebook (2025 Edition)

January 29, 2025 | Posted by Topic(s): Capital Markets; IPOs; Trends and Insights

This guidebook offers an overview of the numerous decision points, procedures and vital considerations a company should contemplate before, during and after the IPO process.

Completing an Initial Public Offering (IPO) is a significant milestone for many business owners, executives, directors and stockholders. However, the journey towards going public can be fraught with complexities and unexpected challenges. For companies seeking to raise capital, whether through an IPO or other alternatives, it is critical to understand the road ahead.

Read More

Webcast: IPO and Public Company Readiness: Advance Planning for 2025 and 2026 IPOs – Corporate Governance and ESG Considerations

November 13, 2024 | Posted by Aaron K. Briggs; Topic(s): Capital Markets; IPOs; Trends and Insights

Please join us for a briefing where we explore corporate governance and ESG considerations in preparing for an Initial Public Offering (IPO) and becoming a public company. We delve into state-of-the-art corporate governance policies and practices that companies should implement in connection with the IPO process, ensuring alignment with market practices and evolving trends. Attendees will gain insights into investor and proxy advisor expectations, key issues under Delaware law and stock exchange listing standards.

Read More

Webcast: Preparing for Stronger Markets: Considerations for IPO Readiness

March 28, 2024 | Posted by Melanie E. Neary; Topic(s): Capital Markets; IPOs; Trends and Insights

As more private companies begin to explore IPOs again after a difficult period in the markets, strong pre-IPO readiness can position companies to more swiftly access IPO market windows when they open. This presentation explores preliminary IPO planning considerations and key issues for private companies thinking about an IPO.

Read More

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Updates

Securities Litigation

Shareholder Activism

Trends and Insights

Editors

Rachel Baron

Branden C. Berns

Lindsay Bernsen Wardlaw

Aaron K. Briggs

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

James Moloney

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan Phillips

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Adam Smith

Karen A. Spindler

Eric J. Stock

Hong Tran

Todd J. Trattner

Stephen Weissman

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.